Dear Anabela,

TrialScope’s disclosure solution simplifies the complexities of clinical trial transparency for trial sponsors. Our customers, who comprise more than 20 of the largest global biopharmaceutical companies, represent approximately 40% of all CTAs publicly available on EU CTR and more than 58% of the results records. 

To support these leading trial sponsors, TrialScope continues to evolve our disclosure solution, including support for EudraCT and the new EU portal. To develop a robust and high-quality system — one that will allow sponsors to submit accurate, timely data to the new EU portal — requires TrialScope to have early and direct access to the portal test environment. To date, this direct access has been granted only to selected trial sponsors participating in testing of the portal. 

On behalf of our customers, we request access to the portal to begin development. In the spirit of partnership, we envision the EMA benefiting as well; we can significantly reduce the workload on the EU support team by acting as the initial point of contact for almost half of all the submissions to the future portal.

Our request is supported by the following TrialScope customers:

<Final List Provided to EMA upon customer signatures>